Effects of Misoprostol on Induction of Labour in Patients with Hypertensive Disorders of Pregnancy: A Meta-Analysis
- PMID: 35432818
- PMCID: PMC9012620
- DOI: 10.1155/2022/8448690
Effects of Misoprostol on Induction of Labour in Patients with Hypertensive Disorders of Pregnancy: A Meta-Analysis
Retraction in
-
Retracted: Effects of Misoprostol on Induction of Labour in Patients with Hypertensive Disorders of Pregnancy: A Meta-Analysis.J Healthc Eng. 2023 Oct 4;2023:9858159. doi: 10.1155/2023/9858159. eCollection 2023. J Healthc Eng. 2023. PMID: 37829400 Free PMC article.
Abstract
Objective: Hypertensive disorders of pregnancy (HDP) can cause serious prenatal and postnatal complications and is a threat to maternal and fetal health. To offer guidance for clinical decisions, we systematically reviewed the effects of misoprostol on induction of labour in HDP patients.
Methods: PubMed, Web of Science, Embase, CNKI, and Wanfang databases were searched for relevant literature from 2010 to 2020. Subsequently, a meta-analysis was performed to compare the effective rate of induction of labour and reducing postpartum hemorrhage (PPH) between the intervention group (n = 544, misoprostol) and the control group (n = 543, oxytocin).
Results: A total of 10 studies with 1087 patients were included. The 10 studies compared the effective rate of induction of labour between the two groups and confirmed that the effective rate in the intervention group was significantly higher than that in the control group (OR = 4.37; 95% CI: 2.73, 7.00). Seven studies compared PPH between the groups and showed that it was significantly reduced in the intervention group compared to the control group (SMD = -1.32; 95% CI: -2.05, -0.59; P < 0.0001).
Conclusion: Misoprostol has a high effective rate of induction of labour in HDP patients and is an effective uterotonic agent in reducing PPH. This meta-analysis provides clinicians with meaningful information to help them make evidence-based decisions.
Copyright © 2022 Leilei Wang et al.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures





References
-
- Ghelfi A. M., Ferretti M. V., Staffieri G. J. Tratamiento farmacológico de la hipertensión arterial no severa durante el embarazo, el posparto y la lactancia [Pharmacological treatment of non-severe hypertension during pregnancy, postpartum and breastfeeding. Hipertensión y Riesgo Vascular . 2021;38(3):133–147. doi: 10.1016/j.hipert.2021.01.002. in Spanish. - DOI - PubMed
-
- Gou W., Xue Y. International guidelines of hypertensive disorders of pregnancy and clinical practice in China. Chinese Journal of Practical Gynecology and Obstetrics . 2017;33(6):559–563.
-
- Sibai B., Ross M. Hypertension in gestational diabetes mellitus: pathophysiology and long-term consequences, the journal of maternal-fetal & neonatal medicine, informa healthcare. The Journal of Maternal-Fetal Medicine . 2016;23(3):229–233. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical